Larry Blandford, PharmD

Corrigendum

Corrigendum: Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

08/02/2016

Rick Lifsitz , MBA;

Larry Blandford , PharmD;

In the June 2016 article, “Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?"1 the author and column editor would like to clarify several points....

In the...

08/02/2016

Journal of Clinical Pathways

Pharma Insights

Value Transformation: Observations on the Second Annual Evaluation Report of the Oncology Care Model

03/13/2019

Maureen Hennessey , PhD, CPCC, CPHQ;

Larry Blandford , PharmD;

Linda Bolland , PharmD, MBA;

The Centers for Medicare & Medicaid Services (CMS) posted its second annual evaluation report of the Oncology Care Model (OCM) in December 2018, covering first performance period and model year results. This...

The...

03/13/2019

Journal of Clinical Pathways

Pharma Insights

When Medication Price Deflates Perception of Therapeutic Effect

04/11/2016

Larry Blandford , PharmD;

Stephen C. Carter , BSc;

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

...

04/11/2016

Journal of Clinical Pathways

Special Article

The Solution to More Effective Diabetes Management: Better Products or Better Programs?

12/09/2016

Larry Blandford , PharmD;

Larry Blandford, PharmD, discusses the high costs of diabetes treatment and questions whether better products or better programs are the solution to more effective diabetes care.

Larry Blandford, PharmD,...

12/09/2016

Journal of Clinical Pathways

Pharma Insights

The Challenge With Today’s Value Assessments: Not Evolving With the Evidence

04/16/2019

Larry Blandford , PharmD;

The methodologies employed within value assessments, especially by the Institute for Clinical and Economic Review (ICER), primarily measure value through quality-adjusted life-years (QALYs). While also the common...

The...

04/16/2019

Journal of Clinical Pathways

Pharma Insights

Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?

05/06/2016

David Parker , PhD;

Larry Blandford , PharmD;

We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...

We are...

05/06/2016

Journal of Clinical Pathways

Pharma Insights

The Health Care Ecosystem and Social Determinants of Health: Surveys Suggest the Stage Is Set for Novel Collaborations

05/15/2019

Larry Blandford , PharmD;

Maureen Hennessey , PhD, CPCC, CPHQ;

Dr Hennessey relates her past personal experience with cancer care delivery when her mother was receiving chemotherapy for lung cancer, where an issue with care access could have significantly altered her mother’s...

Dr...

05/15/2019

Journal of Clinical Pathways

Pharma Insights

Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

06/20/2016

Rick Lifsitz , MBA;

Larry Blandford , PharmD;

The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...

The...

06/20/2016

Journal of Clinical Pathways